NCT00513851 - Phase 1 Study of OSI-930 in Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

September 30, 2009

Conditions

Advanced Solid Tumors

Interventions

DRUG

OSI-930

Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity

DRUG

OSI-930

Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity

Trial Locations (3)

University of Colorado Cancer Center, Aurora

Dana-Farber Cancer Institute, Boston

Cancer Research UK Professor of Medical Oncology, Sutton